Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression. The study aims to evaluate the safety and efficacy of Mirvetuximab Soravtansine in treating these cancers, focusing on patients with high folate receptor-alpha expression.
The intervention under investigation is Mirvetuximab Soravtansine, an investigational antibody drug conjugate designed to target and kill cancer cells by delivering a cell-killing drug to those expressing folate receptor alpha.
The study follows a randomized, parallel intervention model with no masking, primarily for treatment purposes. Participants are divided into two groups receiving different dosing schedules of Mirvetuximab Soravtansine, with an additional cohort to determine dosing for patients with moderate hepatic impairment.
The study began on May 28, 2025, with primary completion expected within 24 months. The last update was submitted on July 29, 2025, indicating ongoing recruitment and progress.
This study could impact AbbVie’s stock performance by potentially enhancing its oncology portfolio, especially if results demonstrate significant efficacy. Investors may view this as a positive development in the competitive cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.